The Centers for Medicare & Medicaid Services (CMS) has released the first list of 10 high-cost drugs subject to negotiated price caps under the Inflation Reduction Act, projecting significant savings. For instance, CMS estimates roughly $6 billion in Medicare Part D savings, with $1.5 billion directly benefiting patients

"Under President Biden, the Centers for Medicare & Medicaid Services (CMS) negotiated 2026 pricing for a list of 10 drugs. CMS projects roughly $6 billion in Medicare Part D savings ($1.5B for patients) attributed to the 2026 list."

. This move, impacting drugs with a high out-of-pocket spend, aims to lower costs for essential medications. However, the press releases and initial coverage often overlook the specific mechanisms and limitations of these negotiations. For example, the Maximum Fair Price (MFP) for the 2026 list, the inaugural cohort, differs from subsequent years, with only 30% of the drugs meeting a specific benchmark compared to later cohorts

"In IPAY 2028, 10 out of 15 (67%) drugs on the list met this benchmark, compared to 8 out of 15 (53%) drugs on the IPAY 2027 list, and 3 out of 10 (30%) drugs on the IPAY 2026 list."

. Furthermore, the program is testing a rebate model on specific drugs included on this list, a nuance that could affect how savings are realized

"Per HHS, this limited pilot program would test a rebate model on NDC-11s included on the CMS Medicare Drug Price Negotiation Selected Drug List for year 2026 — drugs with an established MFP. The 2026 list of drugs with MFPs is available here."

.

The initial rollout of Medicare's drug price negotiation program, a key provision of the Inflation Reduction Act, has been met with widespread praise for its projected $6 billion in overall savings, with $1.5 billion directly impacting patients

"Under President Biden, the Centers for Medicare & Medicaid Services (CMS) negotiated 2026 pricing for a list of 10 drugs. CMS projects roughly $6 billion in Medicare Part D savings ($1.5B for patients) attributed to the 2026 list."

. This list of 10 drugs represents the first time Medicare has directly negotiated prescription drug prices, a move long sought by patient advocates. However, the press often frames this as a simple price reduction without detailing the complexities. The Maximum Fair Price (MFP) for this inaugural 2026 list, for example, shows a lower compliance rate with certain benchmarks compared to later negotiation years, indicating that the initial savings might be less dramatic than anticipated for every drug

"In IPAY 2028, 10 out of 15 (67%) drugs on the list met this benchmark, compared to 8 out of 15 (53%) drugs on the IPAY 2027 list, and 3 out of 10 (30%) drugs on the IPAY 2026 list."

. This isn't a price cut across the board; it's a negotiated ceiling that varies significantly.

Beyond the headline price caps, the Centers for Medicare & Medicaid Services (CMS) is also testing pilot programs, including a rebate model specifically for drugs on the 2026 list

"Per HHS, this limited pilot program would test a rebate model on NDC-11s included on the CMS Medicare Drug Price Negotiation Selected Drug List for year 2026 — drugs with an established MFP. The 2026 list of drugs with MFPs is available here."

. While this aims to further refine cost-saving mechanisms, its direct impact on patient out-of-pocket expenses isn't always clear from initial reports. The press releases tend to focus on the broad strokes of negotiation rather than the granular testing of financial models. This pilot approach means the savings might not be as straightforward as a simple sticker price reduction, and understanding how these rebates are applied is key to truly assessing the program's efficacy for individual beneficiaries. It’s less about a simple discount and more about a complex financial experiment.

The 10 drugs selected for the 2026 negotiation are just the beginning. Subsequent years will see more drugs added to the list, with different negotiation cohorts. For instance, the maximum fair prices for the 15 drugs in IPAY 2027 and beyond show different characteristics and potentially deeper discounts compared to the initial 2026 list [c4, c5]. The initial 30% of drugs meeting specific benchmarks on the 2026 list pales in comparison to the 67% seen in the IPAY 2028 cohort

"In IPAY 2028, 10 out of 15 (67%) drugs on the list met this benchmark, compared to 8 out of 15 (53%) drugs on the IPAY 2027 list, and 3 out of 10 (30%) drugs on the IPAY 2026 list."

. This evolving landscape means that while this first list is historic, its long-term significance will be measured against future negotiations and their expanding impact on drug affordability. The press often treats this as a one-time event, not an ongoing, iterative process.